PRPH — Prophase Labs Income Statement
0.000.00%
Last trade - 00:00
- $95.97m
- $105.62m
- $44.38m
- 12
- 29
- 39
- 16
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 9.88 | 14.5 | 79 | 123 | 44.4 |
Cost of Revenue | |||||
Gross Profit | 2.62 | 4.61 | 42 | 70.7 | 16.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 13.1 | 16.6 | 69.2 | 99.1 | 66 |
Operating Profit | -3.24 | -2.09 | 9.8 | 23.6 | -21.6 |
Total Net Non Operating Interest Income / Expense | |||||
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -3.11 | -2.33 | 5.3 | 22.9 | -22.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.11 | -2.33 | 6.27 | 18.5 | -16.8 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -3.15 | -2.13 | 6.27 | 18.5 | -16.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -3.15 | -2.13 | 6.27 | 19.1 | -16.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.269 | -0.364 | 0.341 | 1.02 | -0.975 |
Special Dividends per Share |